Needham & Company
View Older Stories
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Needham & Company Reiterates Buy Rating on Cara Therapeutics (CARA)
-
Needham & Company Reiterates Cara Therapeutics (CARA) at Buy, Expects EMA Approval of I.V. Korsuva in 2Q22
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
-
Cara Therapeutics (CARA) To See $180M in 2024 Revenue from Korsuva - Needham & Company
-
Cara Therapeutics (CARA) PT Lowered to $26 at Needham & Company After Endpoints Missed in Ph2 KARE Trial
-
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
-
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
-
Companies with NDRs 7/31
-
Companies with NDRs 5/13
-
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference
-
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 5.5M Share Common Offering at $23/Sh
-
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
-
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
-
Cara Therapeutics (CARA) Announces 5M Share Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics (CARA) PT Raised to $35 at Needham & Company
-
Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
-
Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.5M Share Common Offering at $19/Sh
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics (CARA) Announces Proposed 4.5M Share Common Offering
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License Agreement
-
Cara Therapeutics (CARA): Two Reasons To Buy Shares - Needham
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.45M Shares at $18
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics to Webcast Presentation at the 16th Annual Needham Healthcare Conference
-
Needham and Company Reiterates Buy Rating and $23 PT on Cara Therapeutics (CARA) Following Positive CR845 Phase 2/3 Results
-
Cara Therapeutics to Webcast Presentation at the 15th Annual Needham Healthcare Conference
-
Streetinsider.com's Hot Lunchtime Reads 12/9: (DATE) (CARA) (PBY) (SUNE)
-
Cara Therapeutics (CARA) Bullish Stance Reiterated at Needham & Company on Positive Oral CR845 Phase 2 Osteoarthritis Results